# Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer

Source: https://onco.cc/trials/nct03937141/  
OnCo record `nct03937141` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of ADU-S100 in Head and neck squamous cell carcinoma, run by Chinook Therapeutics, Inc. (formerly Aduro), recorded as terminated on the registry.

## Summary

Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer is a phase 2 interventional study registered as NCT03937141 by Chinook Therapeutics, Inc. (formerly Aduro), with 16 participants recorded, started 2019-08-26 and due to reach its primary completion in 2021-05-10. Interventions recorded: ADU-S100. Conditions recorded: Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer.

Linked to the drug ADU-S100 because the registry names it among its interventions and Head and neck squamous cell carcinoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03937141
- Phase: 2
- Setting: A Phase 2 Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Adults With Head and Neck Cancer
- Sponsor: Chinook Therapeutics, Inc. (formerly Aduro)
- Enrolled: 16

## Sources

- ClinicalTrials.gov NCT03937141: https://clinicaltrials.gov/study/NCT03937141

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- drugs: [ADU-S100 (MIW815)](https://onco.cc/drugs/adu-s100/)

---
JSON: https://onco.cc/api/v1/entities/nct03937141.json